Document Type : Short Communication

Authors

1 Pediatrician, Neonatal specialist assistant, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Neonatologist, Professor, Neonatal Research Center, Imam Reza Hospital, Faculty of Medicine, Mashhad, University of Medical Sciences, Mashhad, Iran

3 Neonatologist, Assistant professor, Neonatal Research Center, Imam Reza Hospital, Faculty of Medicine, Mashhad, University of Medical Sciences, Mashhad, Iran.

4 Mashhad university of medical science

5 2Neonatal intensive care nurse. Faculty of Nursing and Midwifery, Mashhad University of Medical Science, Mashhad, Iran.

6 Associated Professor of neonatology, Neonatal research center, faculty of medicine, Mashhad University of Medical, Mashhad, Iran

10.22038/apjmt.2024.78707.1446

Abstract

Introduction: Newborns may be treated with phenobarbital for many reasons. Because in each region, depending on different races and genetic factors, different pharmacokinetic conditions govern the drug. It is essential to control blood levels of certain drugs, especially phenobarbital, and maintain these levels during treatment. In this study, we measure the level of phenobarbital in newborns who receive intravenous.
Methods: In this study, venous blood was collected from 50 neonates who received intravenous phenobarbital at a loading dose of 20 mg/kg weight, and at least, three days had passed since the maintenance dose of 5 mg/kg body weight in 24 hours, and sent to the laboratory. Phenobarbital blood levels were measured, and the results were analyzed descriptively.
Results: In this study, the average weight of newborns in two groups was 9.93 ± 2.58 kg. The mean blood concentration of phenobarbital, three days after starting the maintenance dose in the group of infants weighing more than 2.5 kg was 3.33 ± 9.1 micrograms/liter, in the group of infants weighing less than 2 kg. and half a kilogram or LBW was 5.9 ± 9.5 micrograms/liter, and in the group weighing less than 1.5 kg VLBW was 14.4 ± 15.46 micrograms/liter. There was no significant difference between case and control group (p>0.05). Three days after starting the maintenance dose in all three groups, the mean blood phenobarbital concentration was 9.86 ± 0.86 micrograms/liter.
Conclusion: Blood phenobarbital levels in our newborns are below therapeutic levels at day two, so phenobarbital levels should be evaluated.

Keywords

Main Subjects

  1.  

    1. Lee D C , Ferguson K L sedative hypnotics Nelson LS Lewin N A, Howland M A GoldFrank’ Toxicologic Emergencies  9th ed  McGraw  Hill 2011; 1064-1065
    2. Dawodu T, Douma CE, Patnode R ,Common neonatal intensive care unit medication guidelines, Cloherty JP Erchenwald EC Stark AR Manual of neonatal care  6th ed Wolter Kluwer Lippincott. Williams Wilkins 2008; 706
    3. Lee C, Custer JW Rau RE. Drug doses Custer JW  Rau RE the Harriet lane handbook 18ed Mosby Elsevier 2009; 944
    4. Neville  K A,Leeder J S Pediatric Pharmacogeneticns Pharmacogenomics and Pharmacoproteomics .KliegmanRM Stanton B F, Geme JVST Nelson Textbook of Pediatrics19th ed   elsevier saunders 2011;250
    5. Lobo MG, Pinheiro SM, Castro JG, Momenté VG, Pranchevicius MC. Adverse drug reaction monitoring: support for pharmacovigilance at a tertiary care hospital in Northern Brazil. BMC Pharmacol Toxicol. 2013 Jan 8;14:5. doi: 10.1186/2050-6511-14-5.
    6.  Pippenger CE, Rosen Phenobarbital plasma levels in neonates TS.Clin Perinatol. 1975 Mar;2(1):111-5.
    7.  Karel  A , Brian J; Anker VD, John N et al Clearance in Preterm Neonates: Relation to Prenatal growth Home June 2007; - Volume 29 - Issue 3
    8.  Yukawa M, Yukawa E, Suematsu F, Takiguchi T, Ikeda H, Aki H, Mimemoto M. Population pharmacokinetics of phenobarbital by mixed effect modelling using routine clinical pharmacokinetic data in Japanese neonates and infants: an update. J Clin Pharm Ther. 2011 Dec;36(6):704-10
    9. Pitlick W, Painter M, Pippenger C. Phenobarbital pharmacokinetics in neonates. Clin Pharmacol Ther. 1978 Mar; 23(3):346-50.
    10. Heimann G, Gladtke E. Pharmacokinetics of phenobarbital in childhood. Eur J Clin Pharmacol. 1977; 12:305–310.
    11. Pitlick W, Painter M, Pippenger C. Phenobarbital pharmacokinetics in neonates. Clin Pharmacol Ther. 1978; 23:346–350.
    12. . Fischer JH, Lockman LA, Zaske D, et al. Phenobarbital maintenance dose requirements in treating neonatal seizures. Neurology. 1981; 31: 1042–1044.
    13. Minagawa K, Miura H, Chiba K, et al. Pharmacokinetics and relative bioavailability of intramuscular phenobarbital sodium or acid in infants. Pediatr Pharmacol (New York). 1981; 1:279–289.
    14. Grasela TH Jr, Donn SM. Neonatal population pharmacokinetics of phenobarbital derived from routine clinical data. Dev Pharmacol Ther. 1985; 8:374–383.
    15.  Touw DJ, Graafland O, Cranendonk A, et al. Clinical pharmacokinetics of phenobarbital in neonates. Eur J Pharm Sci. 2000; 12:111–116.
    16. Kokwaro GO, Ogutu BR, Muchohi SN, et al. Pharmacokinetics and clinical effect of phenobarbital in children with severe falciparum malaria and convulsions. Br J Clin Pharmacol. 2003;56:453–457
    17. Offie Porat Soldin* and Steven J. Soldin† Review: Therapeutic Drug Monitoring in Pediatrics February 2002;24(1): 9-14.
    18. Koren G Salivary excretion of drugs in children: theoretical and practical issues in therapeutic drug monitoring. Developmental Pharmacology and Therapeutics 1992, 19(4):161-177.
    19. Edelbroek, Peter M PhD*; Heijden, Jacques van der BSc†; Stolk, Leo M L PhD† Dried Blood Spot Methods in Therapeutic Drug Monitoring: Methods, Assays, and Pitfalls June 2009 ;31(3):327-336.